Lower Costs, More Cures Act of 2021
Latest action · Jun 22, 2021 Read twice and referred to the Committee on Finance.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedJun 22, 2021
- Passed SenateNot reached
- Passed HouseNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Lower Costs, More Cures Act of 2021
This bill establishes and modifies several programs and requirements to address prescription drug prices, particularly in relation to Medicare and Medicaid.
Among other changes, the bill
- requires the Centers for Medicare & Medicaid Services to publish certain information, as reported by pharmacy benefit managers (PBMs), relating to generic dispensing rates, drug discounts and rebates, and payments between PBMs, health plans, and pharmacies;
- caps annual out-of-pocket spending under the Medicare prescription drug benefit;
- allows prescription drug plan sponsors under the Medicare prescription drug benefit to offer additional plans in a region;
- establishes requirements under the Medicaid Drug Rebate Program for certain gene therapies for which prices are indexed to achieved outcomes; and
- establishes the position of Chief Pharmaceutical Negotiator in the Office of the U.S. Trade Representative.
Cosponsors 8
Members who signed on, in the order they did. Signatures ran from Jun 22, 2021 to Sep 6, 2022, with 7 there on the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| R-ID | James E. Risch | Original | Jun 22, 2021 |
| R-IA | Joni Ernst | Original | Jun 22, 2021 |
| R-NC | Richard Burr | Original | Jun 22, 2021 |
| R-KS | Roger Marshall | Original | Jun 22, 2021 |
| R-MT | Steve Daines | Original | Jun 22, 2021 |
| R-NC | Thom Tillis | Original | Jun 22, 2021 |
| R-SC | Tim Scott | Original | Jun 22, 2021 |
| R-ND | John Hoeven | Sep 6, 2022 |
Actions 2
Everything that happened, newest first.
- Jun 22, 2021Introduced in Senate
- Jun 22, 2021Read twice and referred to the Committee on Finance.
Related bills 4
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 1287 | REFUND Act of 2021 | Related bill | Apr 21, 2021 |
| S 2815 | Seniors Saving on Insulin Act | Related bill | Sep 23, 2021 |
| HR 3682 | Improving Transparency to Lower Drug Costs Act of 2021 | Related bill | Jun 2, 2021 |
| HR 4417 | Capping Drug Costs for Seniors Act of 2021 | Related bill | Jul 14, 2021 |
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Business records
- Civil actions and liability
- Congressional oversight
- Consumer affairs
- Department of Health and Human Services
- Digestive and metabolic diseases
- Drug safety, medical device, and laboratory regulation
- Drug therapy
- Executive agency funding and structure
- Food and Drug Administration (FDA)
- Fraud offenses and financial crimes
- Genetics
- Government information and archives
- Government studies and investigations
- Health
- Health care costs and insurance
- Health care coverage and access
- Health care quality
- Health personnel
- Health promotion and preventive care
- Health technology, devices, supplies
- Home and outpatient care
- Inflation and prices
- Manufacturing
- Marketing and advertising
- Medicaid
- Medical research
- Medicare
- Office of the U.S. Trade Representative
- Prescription drugs
- Product development and innovation
- Public participation and lobbying
- Trade agreements and negotiations
Text 1
Each version as it was printed, newest first.
- Jun 22, 2021Introduced in Senate
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov.